skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Targeted treatment of chronic myeloid leukemia: role of imatinib

Review

(2505) Views  (792) Full article downloads

Authors: Ila Tamascar, Jeyanthi Ramanarayanan

Published Date March 2009 Volume 2009:2 Pages 63 - 71
DOI: http://dx.doi.org/10.2147/OTT.S3993

Ila Tamascar, Jeyanthi Ramanarayanan

Department of Medical Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, USA

Abstract: Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by clonal expansion of pleuripotent hematopoetic stem cells. The incidence of CML is 1 to 2 cases per 100,000 people per year; in the Western Hemisphere, CML accounts for 15% of leukemias in adults. Discovery of the specific karyotypic abnormality of the Philadelphia (Ph) chromosome in the pathogenesis of CML has led to a better understanding of the disease and hence to an advancement of targeted therapeutics. Availability of imatinib as an accepted targeted therapy in newly diagnosed patients has changed the treatment paradigm in CML. The majority of CML patients in chronic phase achieve excellent and durable responses with standard-dose imatinib. Mechanisms of primary and secondary resistance to imatinib in CML have been extensively studied and newer tyrosine kinase inhibitors are now being evaluated for clinical use. It is important that at any time the CML treatment and response remain optimal and thus patients on imatinib require continuous monitoring for early detection of resistance. This review will discuss the treatment and guidelines for monitoring CML patients in the imatinib era.

Keywords: BCR-ABL, imatinib, tyrosine kinase inhibitors, leukemia, CML








Readers of this article also read:

Periosteoplasty for covering gingival recessions: Clinical results
Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Enucleation following treatment with intravenous pentamidine for Acanthamoeba sclerokeratitis
Perception of risk and benefit in patient-centered communication and care
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Erratum